DBV Technologies (DBVT) Free Cash Flow (2020 - 2026)
DBV Technologies (DBVT) reported Free Cash Flow of -$49.5 million for Q1 2026, down 151.27% year-over-year from $96.5 million in Q1 2025, and down 39.26% quarter-over-quarter from -$35.5 million in Q4 2025.
DBV Technologies (DBVT) Free Cash Flow (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Free Cash Flow data on file, last reported at -$49.5 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$49.5 million, down 151.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$151.5 million (down 67.45% YoY), and the FY2025 annual result was -$121.7 million, down 13.95% from the prior year.
- Free Cash Flow fell to -$49.5 million in Q1 2026 per DBVT's latest filing, from -$35.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.6 million in Q1 2022 and troughed at -$49.5 million in Q1 2026.
- A 5-year average of -$24.4 million and a median of -$22.9 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 95.56% in 2022, then slumped 1198.14% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$23.9 million in 2022, then jumped by 41.26% to -$14.0 million in 2023, then grew by 13.61% to -$12.1 million in 2024, then tumbled by 193.11% to -$35.5 million in 2025, then plunged by 39.26% to -$49.5 million in 2026.
- Business Quant data shows DBVT's Free Cash Flow at -$49.5 million in Q1 2026, -$35.5 million in Q4 2025, and -$32.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | -49.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.50 Mn |
| Mar 31, 2026 | -49.50 Mn |
| Dec 31, 2025 | -35.55 Mn |
| Dec 31, 2025 | -35.55 Mn |
| Sep 30, 2025 | -32.55 Mn |
| Sep 30, 2025 | -32.55 Mn |
| Jun 30, 2025 | -33.92 Mn |
| Jun 30, 2025 | -33.92 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Dec 31, 2024 | -12.13 Mn |
| Dec 31, 2024 | -12.13 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -35.81 Mn |
| Jun 30, 2024 | -35.81 Mn |
| Mar 31, 2024 | -36.03 Mn |
| Mar 31, 2024 | -36.03 Mn |
| Dec 31, 2023 | -14.04 Mn |
| Dec 31, 2023 | -14.04 Mn |